Zomedica Corp

Zomedica Corp’s senior executive increases stake, signaling confidence and potential growth for the veterinary biopharmaceutical company amid a challenging market.

Zomedica Corp. tops 2025 with $32 M revenue and 68% gross margin, driven by PulseVet® and Assisi® devices—record growth and strong liquidity for pet‑health R&D.

Explore Zomedica Corp’s volatile stock, negative earnings, and Moichor partnership—what it means for investors and the veterinary biopharma market.

Explore Zomedica Corp’s volatile stock, negative earnings, and R&D push in veterinary biopharma—what it means for investors and the future.

Discover how Zomedica Corp’s new VETGuardian PLUS™ Monitor could reshape pet‑care tech—while its financials reveal the tight trade‑off between innovation and growth.

Discover how Zomedica Corp’s veterinary biopharmaceutical innovations are reshaping pet healthcare, its market performance, and future prospects.

Explore how Zomedica Corp’s biopharma innovations are boosting pet health and transforming veterinary medicine—discover their research, market trends, and future plans.

Zomedica Corp. reported a 14% increase in revenue to $7 million in Q2 2025, marking its 18th consecutive quarter of record year-over-year revenue.

Zomedica Corp, a veterinary biopharmaceutical company, will present at the OTCQB Venture Virtual Investor Conference on August 7th, 2025, to share its vision and answer investor questions.

Zomedica Corp. has partnered with the World Equestrian Center to make its PulseVet shock wave device the official therapy provider, enhancing equine health and care at the premier equestrian venue.